DURECT Corp Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol Transcript
Greetings and welcome to the Durect Corporation Phase 2b AHFIRM Topline results call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Tim Papp, Chief Financial Officer. Please go ahead.
Thank you, Stacy. Good afternoon, and welcome to everyone joining us today. During this call, we will be discussing the topline data from our Phase 2b AHFIRM trial studying larsucosterol as a potential treatment for alcohol-associated hepatitis and next steps for the program. Before we begin, I encourage everyone to go to the Investor section of our corporate website to view the press release.
I would like to draw your attention to Slide 2, which contains our forward-looking statements. During the course of this call, we will make forward-looking statements regarding the results and clinical data from the AHFIRM trial, development plans for larsucosterol, expected product benefits, market potential, regulatory plans, potential regulatory approval, and the company's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |